43 citations
,
July 1984 in “Clinical and Experimental Dermatology” Antiandrogen therapy helped increase hair growth in women with hormonal imbalances related to baldness.
July 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Trazodone and chlorpromazine may help treat sexual dysfunction caused by finasteride and SSRIs.
November 2020 in “Universal Journal of Pharmaceutical Research” Tacrolimus is a better option than cyclosporine due to fewer side effects.
April 2023 in “Journal of The American Academy of Dermatology” Some drugs linked to growth hormones may increase the chance of hair loss in women.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
17 citations
,
May 2011 in “Movement Disorders” Finasteride significantly reduced tics and obsessive-compulsive symptoms in patients with Tourette syndrome.
1 citations
,
October 2025 in “Cureus” Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
15 citations
,
April 1997 in “Muscle & Nerve” 5 citations
,
April 1997 in “Muscle & Nerve”
May 2024 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” Effective treatments for trichotillomania include cognitive-behavioral therapy, certain medications, and alternative support tools.
September 2010 in “Zhonghua miniao waike zazhi” Tamsulosin hydrochloride is safe and effective for long-term treatment of urinary symptoms in BPH patients.
December 2016 in “The Journal of Sexual Medicine” Short-acting testosterone injections in a clinic are a preferred treatment for low testosterone because they work well, are convenient, and patients stick with the treatment.
February 2016 in “PubMed” Properly administered testosterone therapy is safe and effective but often not covered by insurance.
66 citations
,
January 2008 in “Pharmacology Biochemistry and Behavior” AC-5216 reduces anxiety in mice through neurosteroids affecting GABAA receptors.
July 2013 in “Revista da Universidade Vale do Rio Verde” Flutamide treatment showed no significant changes in mice vaginal mucosa.
3 citations
,
July 2025 in “International Immunopharmacology” April 2025 in “Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )” Cuscuta reflexa extract may help treat benign prostatic hyperplasia by reducing inflammation and oxidative stress.
7 citations
,
January 1994 in “Annual Reports in Medicinal Chemistry” Understanding how androgens work is key for creating new treatments for prostate issues and hair/skin conditions.
January 2021 in “Research Portal Denmark” Tofacitinib helped a man with alopecia totalis regrow all his hair.
Finasteride may help treat childhood brain tumors by activating certain genes.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
6 citations
,
November 2010 in “International Journal of Andrology” New oral testosterone formulations show potential for safer, effective hormone replacement in men with low testosterone.
14 citations
,
October 2015 in “Neurochemistry International” Letrozole may help prevent seizures by reducing certain hormone levels.
1 citations
,
May 2026 in “Journal of Dermatological Treatment” JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.
August 2021 in “Skin appendage disorders” Two people lost hair unexpectedly after getting a common hair loss treatment with a drug called Dutasteride.
July 2025 in “Scientific Reports” Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
August 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Dutasteride effectively treats hair loss and prostate issues.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.